BioPharma Resources

Drugs by condition

Drugs approved for als (amyotrophic lateral sclerosis)

Brand-name prescription drugs and biologics whose FDA label lists als (amyotrophic lateral sclerosis) as an approved use. Matched on the label phrases: "amyotrophic lateral sclerosis".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

3

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

1

New molecular entities and new biologics

In development

22

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for als (amyotrophic lateral sclerosis).

  • Qalsody (Tofersen) · Biogen Ma NovelAccelerated approvalPriority reviewOrphanApr 25, 2023
  • Radicava Ors (Edaravone) · Shionogi Priority reviewOrphanMay 12, 2022
  • Tiglutik Kit (Riluzole) · Italfarmaco SA OrphanSep 5, 2018

All approved drugs for als (amyotrophic lateral sclerosis), by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 6 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Antisense Oligonucleotide (1)

  • Qalsody Tofersen · Biogen Ma · 2023

Benzothiazole (1)

Class not listed in FDA's data (1)

Drugs in development for als (amyotrophic lateral sclerosis)

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • MasitinibAB1010Phase 33 trials

    AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • PridopidinePhase 32 trials

    Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease

  • Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy

  • COYA 302Phase 31 trial

    Coya Therapeutics · Amyotrophic Lateral Sclerosis (ALS)

  • ION363Phase 31 trial

    Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis

  • MN-166ibudilastPhase 31 trial

    MediciNova · Amyotrophic Lateral Sclerosis

  • ALT001Phase 22 trials

    Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. · Ischemic Stroke in the Sequelae Stage, Amyotrophic Lateral Sclerosis (ALS)

  • CNMAu8gold nanocrystalsPhase 22 trials

    Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis

  • Foralumab NasalPhase 22 trials

    Tiziana Life Sciences LTD · ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS

  • VHB937Phase 22 trials

    Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease

  • AMT-162Phase 21 trial

    UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis

  • AP-101Phase 21 trial

    AL-S Pharma · Amyotrophic Lateral Sclerosis

  • BIIB147Phase 21 trial

    Biogen · Amyotrophic Lateral Sclerosis

  • CORT113176DazucorilantPhase 21 trial

    Corcept Therapeutics · Amyotrophic Lateral Sclerosis

  • FHND1002Phase 21 trial

    Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. · Amyotrophic Lateral Sclerosis (ALS)

  • LTX-002Phase 21 trial

    Leal Therapeutics, Inc · Amyotrophic Lateral Sclerosis

  • NB-4746Phase 21 trial

    Nura Bio · Amyotrophic Lateral Sclerosis (ALS)

  • NX210cPhase 21 trial

    Axoltis Pharma · Amyotrophic Lateral Sclerosis

  • PLL001Phase 21 trial

    PLL TX AUSTRALIA PTY LTD · Amyotrophic Lateral Sclerosis, ALS

More on als (amyotrophic lateral sclerosis): recruiting trials · published research

Related in neurology: Alzheimer's disease · Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.